Cargando…
Advances and limitations for the treatment of spinal muscular atrophy
Spinal muscular atrophy (5q-SMA; SMA), a genetic neuromuscular condition affecting spinal motor neurons, is caused by defects in both copies of the SMN1 gene that produces survival motor neuron (SMN) protein. The highly homologous SMN2 gene primarily expresses a rapidly degraded isoform of SMN prote...
Autores principales: | Day, John W., Howell, Kelly, Place, Amy, Long, Kimberly, Rossello, Jose, Kertesz, Nathalie, Nomikos, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632131/ https://www.ncbi.nlm.nih.gov/pubmed/36329412 http://dx.doi.org/10.1186/s12887-022-03671-x |
Ejemplares similares
-
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
por: Barrett, Doreen, et al.
Publicado: (2021) -
Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018) -
Editorial: Advances in spinal muscular atrophy
por: Sun, Jianli
Publicado: (2023) -
Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021) -
Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)